David A. Barbie, MD

Medical Oncology

MAKE AN APPOINTMENT

Contact Information

Office Phone Number

617-632-6049

Fax

617-632-5786

Appointments

877-332-4294

Biography

David A. Barbie, MD

Dr. Barbie is the Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. He is also Associate Director of the Belfer Center for Applied Cancer Science, as well as an Associate Member of the Broad Institute. Dr. Barbie earned his undergraduate degree at Harvard College and M.D. degree at Harvard Medical School and was a Howard Hughes Medical Investigator Program Medical Student Research Fellow in Dr. Edward Harlow's laboratory at the MGH Cancer Center. He then completed an MGH internal medicine residency and chief medical residency, a Dana-Farber Partners Oncology fellowship, and performed his post-doctoral work in Dr William Hahn's laboratory at Dana-Farber and the Broad Institute. Currently, he is the principal investigator of his own laboratory at Dana-Farber while also seeing patients in the Lowe Center for Thoracic Oncology.

Researcher

Physician

Director, Lowe Center for Thoracic Oncology

Associate Director, Belfer Center for Applied Cancer Research

Jane Rodgers Chair at Dana-Farber

Physician

Professor of Medicine, Harvard Medical School

Centers/Programs

Thoracic Oncology

Clinical Interests

KRAS targeted therapy, Lung cancer, Translational oncology

Diseases Treated

Lung Cancer, non-small cell

Lung Cancer, small cell

Mesothelioma

Thymoma/Thymic Tumors

Board Certification

Internal Medicine, 2005
Medical Oncology, 2008

Fellowship

Dana-Farber/Partners CancerCare, Medical Oncology

Residency

Massachusetts General Hospital, Chief Resident in Internal Medicine
Massachusetts General Hospital, Internal Medicine

Medical School

Harvard Medical School

Recent Awards

NIH R01 Award

2015
V Foundation Scholar Award

2012
ASCO Young Investigator Award 2009
NIH K08 Award 2010

Research

View Dr. Barbie’s Research

Translational Oncology/KRAS Targeted Therapy

My interest as a medical oncologist and cancer biologist is to identify novel targets for cancer therapy. Specifically, I have focused on lung cancer clinically with a particular interest in targeting KRAS mutations, which have remained refractory to current therapies.

We previously found that TBK1, a kinase that is normally involved in immune cell signaling, prevents apoptosis in cancer cells driven by oncogenic KRAS. Others have found that inhibition of the NF-kB and STAT pathways, in which TBK1 is involved, also results in impaired tumor growth in KRAS-driven mouse lung cancer. Recently, we discovered that a kinase inhibitor, momelotinib, inhibits TBK1 and JAK signaling and has activity in mouse models of Kras-driven lung cancer. Based on these findings, we have opened a trial together with Gilead Sciences combining momelotinib with the MEK inhibitor trametinib in treatment refractory KRAS mutant lung cancer.

My overall goal is to continue this effort clinically and in the lab to refine combination therapy for KRAS-driven lung cancer and improve outcomes for this challenging disease.

Support my research